At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
Naltrexone +1 moredrug
Likely dose
Naltrexone 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-Blind Placebo-Controlled Investigation of Naltrexone for Pathological Gambling
In Brief
A Phase 2 clinical trial evaluating Naltrexone and Placebo for Pathological Gambling. Completed, enrolled 9 participants across 3 sites.
Detailed Summary
The investigators plan to investigate the safety, tolerability, and efficacy of the opioid antagonist naltrexone in Pathological Gambling. We hypothesize that naltrexone will be superior to placebo in reducing gambling urges and behavior, when combined with adjuvant non-pharmacological treatment as usual.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPathological Gambling
CountriesUnited States
CollaboratorsNational Center for Responsible Gaming
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedJan 2010
Primary CompletionFeb 2016
Study CompletionJan 2017
TodayJul 2026
First PostedJan 27, 2010
Enrollment StartFeb 1, 2009
Primary CompletionFeb 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 16.4 years ago
Interventions
Naltrexonedrug
Targeted dosage of 50mg PO daily
Placeboother
Sugar pills daily PO